Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FZ-AD004 in Advanced Solid Tumors
NCT05914545Phase 1Recruiting
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Start
- Jun 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of FZ-AD004 in solid tumor, sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Primary endpoints: Dose Limiting Toxicity at 21 days, Maximum Tolerable Dose at 21 days and 2 more. Started Jun 2023; status: recruiting.
02
Drugs
FZ-AD004
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05914545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05914545.